Metagenomi Therapeutics (MGX) Income towards Parent Company (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Income towards Parent Company for 4 consecutive years, with -$23.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 7.91% year-over-year to -$23.1 million; the TTM figure through Mar 2026 stood at -$67.5 million (up 13.43% YoY), while the FY2025 annual figure was -$69.5 million, up 11.01% from the prior year.
• Income towards Parent Company fell to -$23.1 million in Q1 2026 per MGX's latest filing, from -$4.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$4.1 million in Q4 2025 and bottomed at -$25.1 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$18.0 million across 4 years, with a median of -$19.8 million in 2023.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 114.23% — and 2025, when it jumped 82.38%.
• Metagenomi Therapeutics' Income towards Parent Company stood at -$19.3 million in 2023, then fell by 21.27% to -$23.4 million in 2024, then surged by 82.38% to -$4.1 million in 2025, then tumbled by 459.41% to -$23.1 million in 2026.
• Business Quant data shows MGX's Income towards Parent Company at -$23.1 million in Q1 2026, -$4.1 million in Q4 2025, and -$20.4 million in Q3 2025.